The ALS Association and the American Academy of Neurology (AAN) have chosen Professor Ammar Al-Chalabi of King’s College London to receive the 2016 Sheila Essey Award, honoring his contributions to amyotrophic lateral sclerosis (ALS) research and treatment. Ammar Al-Chalabi Dr. Al-Chalabi will be given the…
Molecular Stethoscope, Inc., announced it is working with 23 U.S. academic and medical institutions to further validate its blood-based early diagnostic and disease monitoring tests for hard-to-detect conditions, including amyotrophic lateral sclerosis (ALS) . The San Diego, California-based, company has developed proprietary technology that uses circulating cell-free RNA (ribonucleic acid) in the blood to…
Researchers created a mobile cart device allowing people to communicate via laptops by eye movement alone. The device was designed with severely disabled tetraplegic patients in mind, but it may also help those with decreased upper extremity and hand function, like that caused by amyotrophic lateral sclerosis (ALS), to more easily work with a computer. Shannon…
Origent Data Sciences, Inc., and Cytokinetics, Inc., announced a new research partnership to further refine and validate an Origent computer model to predict the progression of amyotrophic lateral sclerosis (ALS) in patients — a progression that widely varies, making effective clinical trials difficult and costly — by leveraging data from previous and…
AB Science announced that its Phase 2/3 clinical trial evaluating masitinib, the company’s lead compound to treat amyotrophic lateral sclerosis (ALS) patients, has met its primary objective. The ongoing study is currently recruiting participants and expects to finish in June 2017. “The positive outcome of this study in ALS is a significant milestone…
Neuraltus Pharmaceuticals announced that it will initiate a second Phase 2 clinical trial of its investigational drug candidate NP001 for the treatment of amyotrophic lateral sclerosis (ALS), with the intent of confirming positive earlier findings in patients with elevated levels of baseline inflammation and further evaluating the drug’s efficacy. Inflammation is thought to be a…
Leaders in the field of induced pluripotent stem cell (iPSC) – a technology that can help derive motor neurons from people who suffer from amyotrophic lateral sclerosis (ALS) – have published a cutting-edge review, identifying advances and challenges in ALS modeling ability and calling for the development and adoption of rigorous criteria…
ALS.net has just announced the launch of “ALS Unfiltered,” a series of public sessions that will offer expert-led presentations and open conversations about amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), current research status, clinical trials, resources and other topics. The seminars will be held in several cities…
The California Institute for Regenerative Medicine (CIRM)’s Independent Citizens Oversight Committee has approved a $6.3 million grant to fund a research team’s work into a new human embryonic stem cell-based therapy, involving astrocytes, to rescue and restore neurons damaged as a consequence of amyotrophic lateral sclerosis (ALS). Team members, from the University of…
Eisai announced it has withdrawn its new drug application for an ultra-high dose Mecobalamin as a treatment for amyotrophic lateral sclerosis (ALS) in Japan, and is reviewing its next steps in consultation with Japanese regulatory officials. Mecobalamin is one of the co-enzyme forms of vitamin B12. As it is physiologically equivalent…
Get regular updates to your inbox.